Predicted protein targets (top 18)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.55 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.55 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.55 |
| ▸ | ATM | Q13315 | 1/20 | 0.55 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.51 |
| ▸ | ALPL | P05186 | 1/20 | 0.50 |
| ▸ | MPO | P05164 | 1/20 | 0.47 |
| ▸ | NPC1 | O15118 | 1/20 | 0.47 |
| ▸ | RAB9A | P51151 | 1/20 | 0.47 |
| ▸ | MPI | P34949 | 1/20 | 0.47 |
| ▸ | APOBEC3G | Q9HC16 | 1/20 | 0.47 |
| ▸ | LTA4H | P09960 | 2/20 | 0.46 |
| ▸ | LMNA | P02545 | 1/20 | 0.45 |
| ▸ | HPGD | P15428 | 1/20 | 0.45 |
| ▸ | COMT | P21964 | 1/20 | 0.45 |
| ▸ | POLB | P06746 | 1/20 | 0.44 |
| ▸ | ADORA2A | P29274 | 1/20 | 0.44 |
| ▸ | ADORA1 | P30542 | 1/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL28041019 | 0.82 | ALPL (0.51) | ALDH1A1KDM4ECYP2D6ATMALPL | |
| SCHEMBL2041907 | 0.78 | NR1H2 (0.61) | ALDH1A1KDM4EALPLMPONPC1 | |
| SCHEMBL11506547 | 0.74 | NPC1 (0.53) | ALDH1A1KDM4ECYP2D6ATMNPC1 | |
| SCHEMBL21274894 | 0.73 | ALDH1A1 (0.58) | ALDH1A1KDM4ECYP2D6ATMNPSR1 | |
| SCHEMBL22636567 | 0.73 | ALDH1A1 (0.52) | ALDH1A1KDM4ECYP2D6ATMNPSR1 | |
| SCHEMBL23175129 | 0.73 | LMNA (0.70) | ALDH1A1KDM4ECYP2D6ATMNPSR1 | |
| SCHEMBL5789379 | 0.71 | KDM4E (1.00) | ALDH1A1KDM4EALPLNPC1RAB9A | |
| SCHEMBL22636476 | 0.71 | ALDH1A1 (0.47) | ALDH1A1KDM4ECYP2D6ATMNPSR1 | |
| SCHEMBL4853841 | 0.71 | DYRK1A (0.59) | ALDH1A1KDM4ECYP2D6ATMMPO | |
| SCHEMBL3106262 | 0.71 | ALDH1A1 (0.59) | ALDH1A1KDM4ECYP2D6ATMNPSR1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1896434-B1 | SUBSTITUTED HETEROARYL AMIDE MODULATORS OF GLUCOCORTICOID RECEPTOR, AP-1, AND/OR NFkB ACTIVITY AND USE THEREOF | BRISTOL MYERS SQUIBB CO (US) | 2011-02-23 | — | — | EP | disclosed |
| EP-1896434-B1 | SUBSTITUTED HETEROARYL AMIDE MODULATORS OF GLUCOCORTICOID RECEPTOR, AP-1, AND/OR NFkB ACTIVITY AND USE THEREOF | BRISTOL MYERS SQUIBB CO (US) | 2011-02-23 | — | — | EP | disclosed |
| US-7361654-B2 | Substituted heteroaryl amide modulators of glucocorticoid receptor, AP-1, and/or NF-κB activity and use thereof | BRISTOL-MYERS SQUIBB CO. (US) | 2008-04-22 | — | — | US | disclosed |
| US-7361654-B2 | Substituted heteroaryl amide modulators of glucocorticoid receptor, AP-1, and/or NF-κB activity and use thereof | BRISTOL-MYERS SQUIBB CO. (US) | 2008-04-22 | — | — | US | disclosed |
| US-7361654-B2 | Substituted heteroaryl amide modulators of glucocorticoid receptor, AP-1, and/or NF-κB activity and use thereof | BRISTOL-MYERS SQUIBB CO. (US) | 2008-04-22 | — | — | US | disclosed |
| EP-1896434-A1 | SUBSTITUTED HETEROARYL AMIDE MODULATORS OF GLUCOCORTICOID RECEPTOR, AP-1, AND/OR NFkB ACTIVITY AND USE THEREOF | Bristol-Myers Squibb Pharma Company (US) | 2008-03-12 | — | — | EP | disclosed |
| WO-2006076632-A1 | SUBSTITUTED HETEROARYL AMIDE MODULATORS OF GLUCOCORTICOID RECEPTOR, AP-1, AND/OR NFκB ACTIVITY AND USE THEREOF | BRISTOL-MYERS SQUIBB COMPANY (US) | 2006-07-20 | — | — | WO | disclosed |
| US-20060154973-A1 | Substituted heteroaryl amide modulators of glucocorticoid receptor, AP-1, and/or NF-kB activity and use thereof | BRISTOL-MYERS SQUIBB COMPANY | 2006-07-13 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060154973-A1 | Substituted heteroaryl amide modulators of glucocorticoid receptor, AP-1, and/or NF-kB activity and use thereof | NFRKB, NFKB2, NFKB1 | ALDH1A1 4114/4885KDM4E 2102/4885CYP2D6 886/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.